Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.

Oncotarget · 2016 · PMC5342600 · PMID 27487142

Europe PMC DOI

hedged sentence

0.1156

closest p · 2.3× alpha

0.1156

boldest claim

The sentences

borderline significantp = 0.1156not close (p > 0.1)

In the group of patients with a high neutrophil count at baseline, we also observed that bevacizumab improved OS, though the difference was only borderline significant (14.7 months (95% CI: 8.8-18.0) v ersus 10.2 months (95% CI: 8.4-15.9), log rank test p = 0.1156 for patients from experimental versus control arm) (Figure 2A ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.